{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:03:10Z","timestamp":1775624590637,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","award":["2023JH2\/20200091"],"award-info":[{"award-number":["2023JH2\/20200091"]}],"id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303491"],"award-info":[{"award-number":["82303491"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["academicradiology.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Radiology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.acra.2025.01.011","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T15:24:58Z","timestamp":1738769098000},"page":"4678-4688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Diagnostic Performance of PET\/CT Using Different Radiotracers in Clinically Significant Primary Prostate Cancer: A\u00a0Systematic Review and Network Meta-analysis"],"prefix":"10.1016","volume":"32","author":[{"given":"Yiming","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianlu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianbin","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.acra.2025.01.011_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.acra.2025.01.011_bib2","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.acra.2025.01.011_bib3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jama.2014.17943","article-title":"MR\/ultrasound fusion-guided biopsy in prostate cancer: what is the evidentiary standard?","volume":"313","author":"Schwartz","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.acra.2025.01.011_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eururo.2019.06.023","article-title":"Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a cochrane systematic review and meta-analysis","volume":"77","author":"Drost","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.acra.2025.01.011_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.urology.2007.10.022","article-title":"Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years","volume":"72","author":"Rajinikanth","year":"2008","journal-title":"Urology"},{"issue":"11","key":"10.1016\/j.acra.2025.01.011_bib6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrurol.2016.177","article-title":"An update on focal therapy for prostate cancer","volume":"13","author":"Perera","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"6","key":"10.1016\/j.acra.2025.01.011_bib7","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.eururo.2015.01.013","article-title":"Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature","volume":"68","author":"F\u00fctterer","year":"2015","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.acra.2025.01.011_bib8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.acra.2025.01.011_bib9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis","volume":"382","author":"Ahdoot","year":"2020","journal-title":"N Eng J Med"},{"issue":"1","key":"10.1016\/j.acra.2025.01.011_bib10","first-page":"108","article-title":"Evaluating the value of 18F-PSMA-1007 PET\/CT in the detection and identification of prostate cancer using histopathology as the standard","volume":"23","author":"Luo","year":"2023","journal-title":"Cancer Imaging Offl Publ Int Cancer Imaging Soc"},{"issue":"6","key":"10.1016\/j.acra.2025.01.011_bib11","first-page":"847","volume":"63","author":"Sonni","year":"2022","journal-title":"J Nucl Med Offl Publ Soc Nucl Med"},{"issue":"12","key":"10.1016\/j.acra.2025.01.011_bib12","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1097\/RLU.0000000000002289","article-title":"68Ga-PSMA-11 PET\/CT in newly diagnosed prostate adenocarcinoma","volume":"43","author":"Erg\u00fcl","year":"2018","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1016\/j.acra.2025.01.011_bib13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/MOU.0000000000000986","article-title":"The role of novel imaging in prostate cancer focal therapy: treatment and follow-up","volume":"32","author":"Rothberg","year":"2022","journal-title":"Curr Opin Urol"},{"issue":"1","key":"10.1016\/j.acra.2025.01.011_bib14","doi-asserted-by":"crossref","first-page":"2287120","DOI":"10.1080\/15384047.2023.2287120","article-title":"Diagnostic value of 18F-PSMA-1007 PET\/CT for predicting the pathological grade of prostate cancer","volume":"25","author":"Niu","year":"2024","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"10.1016\/j.acra.2025.01.011_bib15","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","article-title":"68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour","volume":"44","author":"Uprimny","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.acra.2025.01.011_bib16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.acra.2025.01.011_bib17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.acra.2025.01.011_bib18","doi-asserted-by":"crossref","unstructured":"Shim S, Yoon BH, Shin IS, Bae JM. Network meta-analysis: application and practice using Stata. Epidemiol Health. 2017; 39:e2017047.","DOI":"10.4178\/epih.e2017047"},{"issue":"7","key":"10.1016\/j.acra.2025.01.011_bib19","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s00259-023-06142-2","article-title":"A prospective comparative study of [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET\/CT imaging in suspicious prostate cancer","volume":"50","author":"Gao","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.acra.2025.01.011_bib20","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/RLU.0000000000004430","article-title":"Comparison of 18 F-PSMA-1007 PET\/CT With 68 Ga-PSMA-11 PET\/CT for initial staging in intermediate- and high-risk prostate cancer","volume":"48","author":"Chandekar","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"7","key":"10.1016\/j.acra.2025.01.011_bib21","first-page":"1076","article-title":"Intraindividual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET\/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study","volume":"59","author":"Giesel","year":"2018","journal-title":"J Nucl Med Offl Publ Soc Nucl Med"},{"issue":"3","key":"10.1016\/j.acra.2025.01.011_bib22","first-page":"379","article-title":"Comparison of 68Ga-PSMA-617 PET\/CT and 68Ga-RM2 PET\/CT in patients with localized prostate cancer who are candidates for radical prostatectomy: a prospective, single-arm, single-center, phase II study","volume":"64","author":"Schollhammer","year":"2023","journal-title":"J Nucl Med Offl Publ Soc Nucl Med"},{"issue":"4","key":"10.1016\/j.acra.2025.01.011_bib23","first-page":"527","article-title":"Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard","volume":"61","author":"Kuten","year":"2020","journal-title":"J Nucl Med Offl Publ Soc Nucl Med"},{"issue":"3","key":"10.1016\/j.acra.2025.01.011_bib24","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2214\/AJR.19.22042","article-title":"Prospective evaluation of 18F-DCFPyL PET\/CT in detection of high-risk localized prostate cancer: comparison with mpMRI","volume":"215","author":"Gaur","year":"2020","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.acra.2025.01.011_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00259-018-4160-7","article-title":"Improved specificity with 68Ga PSMA PET\/CT to detect clinically significant lesions \"invisible\" on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology","volume":"46","author":"Donato","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.acra.2025.01.011_bib26","first-page":"1805","article-title":"Intraindividual comparison of 18F-PSMA-1007 PET\/CT, multiparametric MRI, and radical prostatectomy specimens in patients with primary prostate cancer: a retrospective, proof-of-concept study","volume":"58","author":"Kesch","year":"2017","journal-title":"J Nucl Med Offl Publ Soc Nucl Med"},{"issue":"1","key":"10.1016\/j.acra.2025.01.011_bib27","doi-asserted-by":"crossref","first-page":"10963","DOI":"10.1038\/s41598-020-67385-9","article-title":"Comparison of 68Ga-PSMA-617 PET\/CT with mpMRI for the detection of PCa in patients with a PSA level of 4-20 ng\/ml before the initial biopsy","volume":"10","author":"Li","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.acra.2025.01.011_bib28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.euo.2018.08.011","article-title":"Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography\/computed tomography imaging of newly diagnosed prostate cancer","volume":"2","author":"Touijer","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.acra.2025.01.011_bib29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bju.15929","article-title":"Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer","volume":"131","author":"Doan","year":"2023","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.acra.2025.01.011_bib30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/1754-9485.13084","article-title":"Tumour-capsule interface measured on 18F-DCFPyL PSMA positron emission tomography\/CT imaging comparable to multi-parametric MRI in predicting extra-prostatic extension of prostate cancer at initial staging","volume":"64","author":"Brauchli","year":"2020","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"5","key":"10.1016\/j.acra.2025.01.011_bib31","first-page":"387","article-title":"Localization of primary prostate cancer: FACBC PET\/CT compared with multiparametric MRI using histopathology as reference standard","volume":"11","author":"Hole","year":"2021","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.acra.2025.01.011_bib32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2019.07.005","article-title":"[68Ga-]PSMA-11 PET\/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard - implications for focal radiotherapy planning in primary prostate cancer","volume":"141","author":"Bettermann","year":"2019","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.acra.2025.01.011_bib33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bju.14858","article-title":"Detection and localisation of primary prostate cancer using 68 gallium prostate-specific membrane antigen positron emission tomography\/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology","volume":"126","author":"Kalapara","year":"2020","journal-title":"BJU Int"},{"issue":"10","key":"10.1016\/j.acra.2025.01.011_bib34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/RLU.0000000000001804","article-title":"18F-DCFBC prostate-specific membrane antigen-targeted PET\/CT imaging in localized prostate cancer: correlation with multiparametric mri and histopathology","volume":"42","author":"Turkbey","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.acra.2025.01.011_bib35","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.euo.2023.04.006","article-title":"Head-to-head comparison of 18F-PSMA-1007 positron emission tomography\/computed tomography and multiparametric magnetic resonance imaging with whole-mount histopathology as reference in localisation and staging of primary prostate cancer","volume":"6","author":"Exterkate","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.acra.2025.01.011_bib36","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00330-022-08982-2","article-title":"Value of 68Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I\/II study","volume":"33","author":"Beheshti","year":"2023","journal-title":"Eur Radiol"},{"issue":"6","key":"10.1016\/j.acra.2025.01.011_bib37","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.humpath.2010.02.011","article-title":"Multifocal prostate cancer: biologic, prognostic, and therapeutic implications","volume":"41","author":"Andreoiu","year":"2010","journal-title":"Human Pathol"},{"issue":"1","key":"10.1016\/j.acra.2025.01.011_bib38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/j.semnuclmed.2023.07.001","article-title":"PSMA PET\/CT for primary staging of prostate cancer - an updated overview","volume":"54","author":"Jochumsen","year":"2024","journal-title":"Semin Nucl Med"},{"issue":"9","key":"10.1016\/j.acra.2025.01.011_bib39","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00259-021-05210-9","article-title":"Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis","volume":"48","author":"Alberts","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.acra.2025.01.011_bib40","first-page":"51","article-title":"Matched-pair comparison of 68Ga-PSMA-11 PET\/CT and 18F-PSMA-1007 PET\/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy","volume":"61","author":"Rauscher","year":"2020","journal-title":"J Nucl Med Offl Publ Soc Nucl Med"},{"issue":"2","key":"10.1016\/j.acra.2025.01.011_bib41","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.acra.2023.08.044","article-title":"Detection rate of PSMA PET using different ligands in men with biochemical recurrent prostate cancer following radical treatment: a systematic review and meta-analysis of prospective studies","volume":"31","author":"Wu","year":"2024","journal-title":"Acad Radiol"},{"issue":"6","key":"10.1016\/j.acra.2025.01.011_bib42","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1590\/s1677-5538.ibju.2020.0986","article-title":"Performance of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography in the diagnosis of primary prostate cancer: a systematic review and meta-analysis","volume":"48","author":"Hu","year":"2022","journal-title":"Int Braz J Urol"},{"issue":"8","key":"10.1016\/j.acra.2025.01.011_bib43","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.21037\/qims-20-1312","article-title":"Biphasic GA 68-labeled prostate specific membrane antigen-11 positron emission tomography\/computed tomography scans in the differential diagnosis and risk stratification of initial primary prostate cancer","volume":"11","author":"Qin","year":"2021","journal-title":"Quant Imaging Med Surg"},{"issue":"1","key":"10.1016\/j.acra.2025.01.011_bib44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.23736\/S1824-4785.19.03172-8","article-title":"PSMA uptake on [68Ga]-PSMA-11-PET\/CT positively correlates with prostate cancer aggressiveness","volume":"66","author":"Chen","year":"2022","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"13","key":"10.1016\/j.acra.2025.01.011_bib45","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1158\/1078-0432.CCR-21-0749","article-title":"How Accurately does PSMA Inhibitor 18F-DCFPyL-PET-CT image prostate cancer?","volume":"27","author":"True","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.acra.2025.01.011_bib46","doi-asserted-by":"crossref","first-page":"1145759","DOI":"10.3389\/fonc.2023.1145759","article-title":"The diagnostic performance of 18F-DCFPyL PET in patients with suspected prostate cancer: a systemic review and meta-analysis","volume":"13","author":"Pang","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.acra.2025.01.011_bib47","article-title":"Evaluation of 18F-DCFPyL PSMA PET\/CT for prostate cancer: a meta-analysis","volume":"10","author":"Pan","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.acra.2025.01.011_bib48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00259-020-04782-2","article-title":"18F-DCFPyL PET\/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy","volume":"48","author":"Wondergem","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.acra.2025.01.011_bib49","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.acra.2023.09.002","article-title":"Predicting 18F-DCFPyL-PET\/CT scan positivity in prostate cancer patients with biochemical recurrence","volume":"31","author":"Lee","year":"2024","journal-title":"Acad Radiol"},{"issue":"11","key":"10.1016\/j.acra.2025.01.011_bib50","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2967\/jnumed.116.189233","article-title":"Intraindividual comparison of (18)F-PSMA-1007 PET\/CT, multiparametric MRI, and radical prostatectomy specimens in patients with primary prostate cancer: a retrospective, proof-of-concept study","volume":"58","author":"Kesch","year":"2017","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.acra.2025.01.011_bib51","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bju.15929","article-title":"Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer","volume":"131","author":"Doan","year":"2023","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.acra.2025.01.011_bib52","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/1754-9485.13084","article-title":"Tumour-capsule interface measured on 18F-DCFPyL PSMA positron emission tomography\/CT imaging comparable to multi-parametric MRI in predicting extra-prostatic extension of prostate cancer at initial staging","volume":"64","author":"Brauchli","year":"2020","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"1","key":"10.1016\/j.acra.2025.01.011_bib53","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00330-022-08982-2","article-title":"Value of (68)Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [(18)F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I\/II study","volume":"33","author":"Beheshti","year":"2023","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.acra.2025.01.011_bib54","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2967\/jnumed.122.263889","article-title":"Comparison of (68)Ga-PSMA-617 PET\/CT and (68)Ga-RM2 PET\/CT in patients with localized prostate cancer who are candidates for radical prostatectomy: a prospective, single-arm, single-center, phase II study","volume":"64","author":"Schollhammer","year":"2023","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.acra.2025.01.011_bib55","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.euo.2018.08.011","article-title":"Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography\/computed tomography imaging of newly diagnosed prostate cancer","volume":"2","author":"Touijer","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"7","key":"10.1016\/j.acra.2025.01.011_bib56","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2967\/jnumed.117.204669","article-title":"Intraindividual comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET\/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study","volume":"59","author":"Giesel","year":"2018","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.acra.2025.01.011_bib57","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous 68Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer","volume":"70","author":"Eiber","year":"2016","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.acra.2025.01.011_bib58","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pros.24294","article-title":"Pilot study of the diagnostic utility of (89) Zr-df-IAB2M and (68) Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer","volume":"82","author":"Vlachostergios","year":"2022","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.acra.2025.01.011_bib59","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/RLU.0000000000004430","article-title":"Comparison of 18 F-PSMA-1007 PET\/CT With 68 Ga-PSMA-11 PET\/CT for initial staging in intermediate- and high-risk prostate cancer","volume":"48","author":"Chandekar","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1016\/j.acra.2025.01.011_bib60","first-page":"1512","article-title":"Clinical PET imaging in prostate cancer","volume":"37","author":"Wallitt","year":"2017","journal-title":"Radiographics Rev Publ Radiol Soc North Am Inc"},{"issue":"4","key":"10.1016\/j.acra.2025.01.011_bib61","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","article-title":"F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.acra.2025.01.011_bib62","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.3390\/molecules27123862","article-title":"Analysis of pros and cons in using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007: production, costs, and PET\/CT applications in patients with prostate cancer","volume":"27","author":"Maisto","year":"2022","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.acra.2025.01.011_bib63","first-page":"1705","article-title":"18F-Choline PET\/mpMRI for detection of clinically significant prostate cancer: part 2. Cost-effectiveness analysis","volume":"60","author":"Barnett","year":"2019","journal-title":"J Nucl Med Offl Publ Soc Nucl Med"}],"container-title":["Academic Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107663322500011X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107663322500011X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T12:40:34Z","timestamp":1768221634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107663322500011X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S107663322500011X"],"URL":"https:\/\/doi.org\/10.1016\/j.acra.2025.01.011","relation":{},"ISSN":["1076-6332"],"issn-type":[{"value":"1076-6332","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic Performance of PET\/CT Using Different Radiotracers in Clinically Significant Primary Prostate Cancer: A\u00a0Systematic Review and Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Academic Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acra.2025.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Association of Academic Radiology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}